Clinical trial · Observational
Circulating Tumor DNA Exposure in Peripheral Blood
Circulating Tumor DNA Exposure in Peripheral Blood Using a Novel Process: A Feasibility Study
NCT03517332CI-TRIAL-00035873unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adrenocortical Cancer | Adrenal Cortical Carcinoma | ALIAS | 0.90 |
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Other Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma Subjects of cohort 1 must not: • Have been treated for above diagnosed malignancy
- label
- Cohort 2
- description
- Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2). Subjects of cohort 2 must: • Meet the listed matching criteria Subjects of cohort 2 must not: • Have been diagnosed/treated for a malignancy previously
Primary outcomes (1)
- measure
- Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study
- timeFrame
- 28 Months
- description
- The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * This study will include subjects that are diagnosed with a malignancy (cohort 1\) and a negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2). * Subjects of both cohorts must: * Be of age ≥ 18 * Provide written consent for study participation * Subject of cohort 1 must: * Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma Subjects of cohort 2 must: • Meet the listed matching criteria Exclusion Criteria: * Subjects of cohort 1 must not: Have been treated for above diagnosed malignancy * Subjects of cohort 2 must not: * Have been diagnosed/treated for a malignancy previously
References
Publications (0)
Data not yet available
No reference posted for this study.